Acadia Pharmaceuticals Announces Retirement of R&D Head Elizabeth Thompson and Search for Successor

On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development at Acadia Pharmaceuticals Inc., notified the company of her decision to retire for personal reasons. Dr. Thompson, who joined Acadia in 2024, will continue in her current role during a transition period until a successor is appointed. Following the appointment of a new R&D head, she has agreed to serve as a consultant through at least the end of 2026 to ensure scientific and leadership continuity. This consultancy period is specifically intended to cover the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis (ADP) and the transition into early Phase 3 execution. Acadia has officially initiated a search for her replacement. The company confirmed that its clinical programs, including Phase 2 studies of remlifanserin in ADP and Lewy Body Dementia Psychosis (LBDP), remain ongoing and blinded. Dr. Thompson's retirement is not related to any disagreement with the company regarding its operations, policies, or practices.